Cover Image
市場調查報告書

全球黃斑部水腫市場

Global Macular Edema Market 2014-2018

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 307868
出版日期 內容資訊 英文 83 Pages
訂單完成後即時交付
價格
Back to Top
全球黃斑部水腫市場 Global Macular Edema Market 2014-2018
出版日期: 2014年07月07日 內容資訊: 英文 83 Pages
簡介

黃斑部水腫,是由於視網膜的黃斑部液狀的成分積聚而發病。該疾病的患病原因,有糖尿病、老齡化黃斑部病變(AMD)、視網膜靜脈阻塞症(RVO)等。全球黃斑部水腫市場,預計從2013年到2018年,以9.1%的年複合成長率擴大。

本報告提供全球黃斑部水腫市場趨勢與未來的成長預測、各治療類型趨勢、市場成長因素與課題、主要供應商的資訊等。

第1章 摘要整理

第2章 簡稱清單

第3章 調查範圍

  • 市場概要
  • 主要的產品

第4章 市場調查手法

  • 市場調查流程
  • 調查手法

第5章 疾病概要

第6章 簡介

第7章 市場形勢

  • 市場概要
  • 市場規模與預測
  • 主要藥物的市場分析
    • Lucentis
    • Eylea
  • 其他有潛力藥劑的市場分析
    • Ozurdex
    • Iluvien
  • 波特的五力分析

第8章 各分子類型的市場區隔

組調換蛋白質 小分子

第9章 地理區分

第10章 購買標準

第11章 市場成長因素

第12章 成長因素與其影響

第13章 市場課題

第14章 成長因素與課題的影響

第15章 市場趨勢

第16章 趨勢與其影響

第17章 業者情勢

  • 競爭模式
    • 主要消息
    • M&A
  • 市場佔有率分析
  • 其他卓越供應商

第18章 主要供應商分析

  • Bayer AG
  • F. Hoffmann La Roche Ltd.
  • Novartis AG
  • Regeneron Pharmaceuticals Inc.

第19章 相關報告

目錄
Product Code: IRTNTR3767

About Macular Edema

Macular edema results from fluid accumulation in the macular region of the retina. Macular edema arises from various etiologies such as diabetes, AMD, and RVO. Macular edema disrupts the central vision due to swelling of the macula. Currently, the treatment plan involves the use of surgical and laser therapies as well as drugs such as anti-VEGF therapies and NSAIDs. Surgery and laser therapy are intended to prevent further damage to vision. However, anti-VEGF therapies have been reported to improve the vision loss associated with macular edema.

TechNavio's analysts forecast the Global Macular Edema market will grow at a CAGR of 9.1 percent over the period 2014-2018.

Covered in this Report

This report covers the present scenario and the growth prospects of the Global Macular Edema market for the period 2013-2018. To calculate the market size, the report considers revenue generated through the sales of various drugs administered to treat macular edema associated with distinct etiologies.

The report also presents the vendor landscape and a corresponding detailed analysis of the top vendors in the Global Macular Edema market. In addition, it discusses the major drivers that influence the growth of the market. It also outlines the challenges faced by the vendors and the market at large, as well as the key trends that are emerging in the market.

TechNavio's report, the Global Macular Edema Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas and the EMEA and APAC regions; it also covers the Global Macular Edema market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Key Regions

  • Americas
  • EMEA
  • APAC

Key Vendors

  • Bayer AG
  • F. Hoffmann-La Roche Ltd.
  • Novartis AG
  • Regeneron Pharmaceuticals Inc.

Other Prominent Vendors

  • Alcon Inc.
  • Alimera Sciences Inc.
  • Allergan Inc.
  • Ampio Pharmaceuticals Inc.
  • iCo Therapeutics Inc.
  • Pfizer Inc.
  • Santen Pharmaceutical Co. Ltd.

Key Market Driver

  • Increase in Patient Population

For a full, detailed list, view our report.

Key Market Challenge

  • Increasing Use of Off-label Drugs

For a full, detailed list, view our report.

Key Market Trend

  • Increasing Recommendations by NICE

For a full, detailed list, view our report.

Key questions answered in this report:

  • What will the market size be in 2018 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

  • 03.1. Market Overview
  • 03.2. Product Offerings

04. Market Research Methodology

  • 04.1. Market Research Process
  • 04.2. Research Methodology

05. Disease Overview

06. Introduction

07. Market Landscape

  • 07.1. Market Overview
  • 07.2. Market Size and Forecast
  • 07.3. Market Analysis of Major Drugs
    • 07.3.1. Lucentis
    • 07.3.2. Eylea
  • 07.4. Market Analysis of Other Prominent Drugs
    • 07.4.1. Ozurdex
    • 07.4.2. Iluvien
  • 07.5. Five Forces Analysis

08. Market Segmentation by Molecule Type

  • 08.1.1. Recombinant Protein
  • 08.1.2. Small Molecule

09. Geographical Segmentation

10. Buying Criteria

11. Market Growth Drivers

12. Drivers and their Impact

13. Market Challenges

14. Impact of Drivers and Challenges

15. Market Trends

16. Trends and their Impact

17. Vendor Landscape

  • 17.1. Competitive Scenario
    • 17.1.1. Key News
    • 17.1.2. Mergers and Acquisitions
  • 17.2. Market Share Analysis 2013
  • 17.3. Other Prominent Vendors and Future Vendors

18. Key Vendor Analysis

  • 18.1. Bayer AG
    • 18.1.1. Key Facts
    • 18.1.2. Business Overview
    • 18.1.3. Business Segmentation
    • 18.1.4. Business Segmentation by Revenue 2012 and 2013
    • 18.1.5. Sales by Geography
    • 18.1.6. Business Strategy
    • 18.1.7. Key Information
    • 18.1.8. SWOT Analysis
    • 18.1.9. Strengths
    • 18.1.10. Weaknesses
    • 18.1.11. Opportunities
    • 18.1.12. Threats
  • 18.2. F. Hoffmann La Roche Ltd.
    • 18.2.1. Key Facts
    • 18.2.2. Business Overview
    • 18.2.3. Business Segmentation
    • 18.2.4. Business Segmentation by Revenue 2012 and 2013
    • 18.2.5. Sales by Geography
    • 18.2.6. Business Strategy
    • 18.2.7. Key Information
    • 18.2.8. SWOT Analysis
    • 18.2.9. Strengths
    • 18.2.10. Weaknesses
    • 18.2.11. Opportunities
    • 18.2.12. Threats
  • 18.3. Novartis AG
    • 18.3.1. Key Facts
    • 18.3.2. Business Overview
    • 18.3.3. Business Segmentation by Revenue 2013
    • 18.3.4. Business Segmentation by Revenue 2012 and 2013
    • 18.3.5. Sales by Geography
    • 18.3.6. Business Strategy
    • 18.3.7. Key Developments
    • 18.3.8. SWOT Analysis
    • 18.3.9. Strengths
    • 18.3.10. Weaknesses
    • 18.3.11. Opportunities
    • 18.3.12. Threats
  • 18.4. Regeneron Pharmaceuticals Inc.
    • 18.4.1. Key Facts
    • 18.4.2. Business Overview
    • 18.4.3. Product Segmentation
    • 18.4.4. Revenue Product Segmentation
    • 18.4.5. Business Strategy
    • 18.4.6. Key Information
    • 18.4.7. SWOT Analysis
    • 18.4.8. Strengths
    • 18.4.9. Weaknesses
    • 18.4.10. Opportunities
    • 18.4.11. Threats

19. Other Reports in this Series

List of Exhibits:

  • Exhibit 1: Market Research Methodology
  • Exhibit 2: Global Macular Edema Market 2013-2018 (US$ billion)
  • Exhibit 3: Timeline of Key Regulatory Approvals of Lucentis
  • Exhibit 4: Geography-wise Segmentation of Lucentis Sales (US$ million)
  • Exhibit 5: Lucentis' Revenue 2006-2013 (US$ million)
  • Exhibit 6: Timeline of Key Regulatory Approvals and Filings of Eylea
  • Exhibit 7: Geography-wise Segmentation of Eylea Sales (US$ million)
  • Exhibit 8: Eylea's Revenue 2011-2013 (US$ million)
  • Exhibit 9: Global Macular Edema Market Segmentation by Molecule Type
  • Exhibit 10: Global Macular Edema Market by Geographical Segmentation 2013
  • Exhibit 11: Global Macular Edema Market Share Analysis 2013
  • Exhibit 12: Bayer AG: Business Segmentation 2013
  • Exhibit 13: Bayer AG: Business Segmentation by Revenue 2012 and 2013 (US$ million)
  • Exhibit 14: Bayer AG: Sales by Geography 2013
  • Exhibit 15: Business Segmentation of F. Hoffmann-La Roche Ltd. 2013
  • Exhibit 16: F. Hoffmann-La Roche Ltd: Business Segmentation by Revenue 2012 and 2013
  • Exhibit 17: F. Hoffmann-La Roche Ltd: Sales by Geography 2013 (Pharmaceuticals Division)
  • Exhibit 18: F. Hoffmann-La Roche Ltd: Sales by Geography 2013 (Diagnostics Division)
  • Exhibit 19: Novartis AG: Business Segmentation by Revenue 2013
  • Exhibit 20: Novartis AG: Business Segmentation by Revenue 2012 and 2013 (US$ million)
  • Exhibit 21: Novartis AG: Sales by Geography 2013
  • Exhibit 22: Regeneron Pharmaceuticals Inc.: Product Segmentation
  • Exhibit 23: Regeneron Pharmaceuticals Inc.: Revenue Product Segmentation 2013
Back to Top